Contact
searchSearch
HMP Global

September 2011 - FRMC

Cited Studies on Biomarker Discoveries Prone to Exaggerating Effects
09/19/2011
Christin Melton
Studies are increasingly linking biomarkers to disease risk, treatment response, and disease progression. A recent literature review in the Journal of the American Medical Association [2011;305(21):2200-2207] indicates that some associations...
Studies are increasingly linking biomarkers to disease risk, treatment response, and disease progression. A recent literature review in the Journal of the American Medical Association [2011;305(21):2200-2207] indicates that some associations...
Studies are increasingly linking...
09/19/2011
First Report Managed Care
Telaprevir Improves Outcomes in Some Patients with Hepatitis C
09/19/2011
Christin Melton
Chicago—An analytic model used to calculate long-term outcomes for hypothetical patients with the hepatitis C virus (HCV) projected that patients treated with a combination of telaprevir and peginterferon/ribavirin (PR) would survive between...
Chicago—An analytic model used to calculate long-term outcomes for hypothetical patients with the hepatitis C virus (HCV) projected that patients treated with a combination of telaprevir and peginterferon/ribavirin (PR) would survive between...
Chicago—An analytic model used...
09/19/2011
First Report Managed Care
Linaclotide Significantly Improves Quality of Life and Abdominal Symptoms
09/19/2011
Christin Melton
Trials comparing linaclotide with placebo found that a daily dose reduced the severity of chronic constipation and improveed quality of life. 
Trials comparing linaclotide with placebo found that a daily dose reduced the severity of chronic constipation and improveed quality of life. 
Trials comparing linaclotide...
09/19/2011
First Report Managed Care
Comparing Adjuvant Chemotherapy Regimens in Non–Small-Cell Lung Cancer
09/19/2011
Tim Casey
Chicago—A randomized phase 2 trial found that cisplatin plus pemetrexed was a safe and effective adjuvant chemotherapy regimen for patients with early-stage non–small-cell lung cancer (NSCLC). Patients taking cisplatin plus pemetrexed...
Chicago—A randomized phase 2 trial found that cisplatin plus pemetrexed was a safe and effective adjuvant chemotherapy regimen for patients with early-stage non–small-cell lung cancer (NSCLC). Patients taking cisplatin plus pemetrexed...
Chicago—A randomized phase 2...
09/19/2011
First Report Managed Care
Six-Year Follow-Up of Lenalidomide for Multiple Myeloma
09/19/2011
Tim Casey
Chicago—After 6 years of follow-up in a phase 2 trial, researchers found that a combination therapy of dexamethasone, lenalidomide, and clarithromycin remained an effective regimen for patients who were newly diagnosed with multiple myeloma....
Chicago—After 6 years of follow-up in a phase 2 trial, researchers found that a combination therapy of dexamethasone, lenalidomide, and clarithromycin remained an effective regimen for patients who were newly diagnosed with multiple myeloma....
Chicago—After 6 years of...
09/19/2011
First Report Managed Care
Glucose-Lowering Effect of Insulin Degludec
09/19/2011
Tim Casey
San Diego—In a randomized, double-blind, 2-period, crossover trial, researchers found the glucose-lowering effect of insulin degludec was evenly distributed in the first and second 12-hour periods in patients with type 2 diabetes. They also...
San Diego—In a randomized, double-blind, 2-period, crossover trial, researchers found the glucose-lowering effect of insulin degludec was evenly distributed in the first and second 12-hour periods in patients with type 2 diabetes. They also...
San Diego—In a randomized,...
09/19/2011
First Report Managed Care
Cost of Comorbidities in Obese Adults
09/19/2011
Tim Casey
San Diego—Using data from research databases, researchers confirmed that patients with a body mass index (BMI) ≥35 kg/m2 had a higher prevalence of and costs associated with comorbidities compared with patients who had a BMI between 25 and...
San Diego—Using data from research databases, researchers confirmed that patients with a body mass index (BMI) ≥35 kg/m2 had a higher prevalence of and costs associated with comorbidities compared with patients who had a BMI between 25 and...
San Diego—Using data from...
09/19/2011
First Report Managed Care
Pooled Analysis of Exenatide to Treat Type 2 Diabetes
09/19/2011
Tim Casey
San Diego—A pooled analysis of 16 studies found that patients with type 2 diabetes treated with exenatide twice daily or once weekly had significant improvements in hemoglobin A1c (HbA1c) level, fasting glucose, body weight, and systolic...
San Diego—A pooled analysis of 16 studies found that patients with type 2 diabetes treated with exenatide twice daily or once weekly had significant improvements in hemoglobin A1c (HbA1c) level, fasting glucose, body weight, and systolic...
San Diego—A pooled analysis of...
09/19/2011
First Report Managed Care
Oral Antidiabetics for Type 2 Diabetes and Chronic Kidney Disease
09/19/2011
Tim Casey
San Diego—An examination of electronic health record data from an integrated health system found that patients with type 2 diabetes and chronic kidney disease who had an oral antidiabetic drug regimen concordant with National Kidney...
San Diego—An examination of electronic health record data from an integrated health system found that patients with type 2 diabetes and chronic kidney disease who had an oral antidiabetic drug regimen concordant with National Kidney...
San Diego—An examination of...
09/19/2011
First Report Managed Care
Saxagliptin Safe, Effective after 4 Years
09/19/2011
Tim Casey
San Diego—After examining 4-year extensions of 2 randomized, double-blind, placebo-controlled trials, researchers found that patients with type 2 diabetes who took saxagliptin alone or in combination with metformin tolerated the medication....
San Diego—After examining 4-year extensions of 2 randomized, double-blind, placebo-controlled trials, researchers found that patients with type 2 diabetes who took saxagliptin alone or in combination with metformin tolerated the medication....
San Diego—After examining 4-year...
09/19/2011
First Report Managed Care

Behind the Bill

Behind the Bill
SCOTUS Takes on the Nondelegation Doctrine: Surprising Reactions and What They Mean for Agency Power
04/02/2025
Katie Hayes, MJ
The Supreme Court recently heard arguments in Federal Communication Commission (FCC) v Consumers’ Research, a case that I covered in February and one that could dramatically reshape federal agency authority through the nondelegation...
The Supreme Court recently heard arguments in Federal Communication Commission (FCC) v Consumers’ Research, a case that I covered in February and one that could dramatically reshape federal agency authority through the nondelegation...
The Supreme Court recently heard...
04/02/2025
First Report Managed Care
Behind the Bill
Dr Oz’s Prescription for Making Medicaid “Viable at Every Level”
03/26/2025
Katie Hayes, MJ
On Tuesday, March 25, 2025, the Senate Finance Committee voted to advance Dr Mehmet Oz in his confirmation as the next head of the Centers for Medicare and Medicaid Services (CMS).1 The full Senate vote is expected “soon” (whatever that...
On Tuesday, March 25, 2025, the Senate Finance Committee voted to advance Dr Mehmet Oz in his confirmation as the next head of the Centers for Medicare and Medicaid Services (CMS).1 The full Senate vote is expected “soon” (whatever that...
On Tuesday, March 25, 2025, the...
03/26/2025
First Report Managed Care
Behind the Bill
The $880 Billion Question Continues: Dr Oz's Confirmation and the Future of Medicaid
03/19/2025
Katie Hayes, MJ
Last week, I explored the $880 billion question facing Congress—whether lawmakers could achieve their budget goals without cutting Medicaid. This week, that question took center stage as Dr Mehmet Oz, President Trump's nominee to lead the...
Last week, I explored the $880 billion question facing Congress—whether lawmakers could achieve their budget goals without cutting Medicaid. This week, that question took center stage as Dr Mehmet Oz, President Trump's nominee to lead the...
Last week, I explored the $880...
03/19/2025
First Report Managed Care
Behind the Bill
The $880 Billion Question: Can Congress Cut Spending Without Touching Medicaid?
03/12/2025
Katie Hayes, MJ
I’d like to step away from administrative law for a moment to provide a quick update on Medicaid. With news coming from all sides, what does the future of Medicaid actually look like? The House of Representatives narrowly passed a budget...
I’d like to step away from administrative law for a moment to provide a quick update on Medicaid. With news coming from all sides, what does the future of Medicaid actually look like? The House of Representatives narrowly passed a budget...
I’d like to step away from...
03/12/2025
First Report Managed Care
Behind the Bill
RFK Jr’s Public Comment Ban: The Silent Shift in Health Care Rulemaking
03/05/2025
Katie Hayes, MJ
The erosion of administrative law continues, and with it, the dismantling of decades-long precedent. In June, the Supreme Court overturned a 40-year-old doctrine that allowed federal agencies to interpret their own ambiguous statutes. Later...
The erosion of administrative law continues, and with it, the dismantling of decades-long precedent. In June, the Supreme Court overturned a 40-year-old doctrine that allowed federal agencies to interpret their own ambiguous statutes. Later...
The erosion of administrative...
03/05/2025
First Report Managed Care
Behind the Bill
Prevention Over Pills? The First 2 Weeks of Health Care’s New Direction
02/26/2025
Katie Hayes, MJ
The dust has barely settled from Robert F Kennedy Jr’s confirmation as Secretary of Health and Human Services (HHS), but the changes are already coming fast and furious—a key theme of the Trump Administration’s actions within the last several...
The dust has barely settled from Robert F Kennedy Jr’s confirmation as Secretary of Health and Human Services (HHS), but the changes are already coming fast and furious—a key theme of the Trump Administration’s actions within the last several...
The dust has barely settled from...
02/26/2025
First Report Managed Care
Behind the Bill
The Nondelegation Doctrine: The Next Constitutional Showdown (Part 2)
02/19/2025
Katie Hayes, MJ
Last week, I explored the potential revival of the nondelegation doctrine through Federal Communication Commission v Consumers’ Research. Today, I want to examine what this could mean for health care regulation by considering the parallels...
Last week, I explored the potential revival of the nondelegation doctrine through Federal Communication Commission v Consumers’ Research. Today, I want to examine what this could mean for health care regulation by considering the parallels...
Last week, I explored the...
02/19/2025
First Report Managed Care
Behind the Bill
The Nondelegation Doctrine: The Next Constitutional Showdown (Part 1)
02/12/2025
Katie Hayes, MJ
Just when you thought the dust had settled from the Chevron decision, the Supreme Court is gearing up to hear arguments in Federal Communications Commission v Consumers' Research next month, potentially reviving the long-dormant nondelegation...
Just when you thought the dust had settled from the Chevron decision, the Supreme Court is gearing up to hear arguments in Federal Communications Commission v Consumers' Research next month, potentially reviving the long-dormant nondelegation...
Just when you thought the dust...
02/12/2025
First Report Managed Care
Behind the Bill
No, President Trump Did Not Actually Sign an Executive Order That Would Increase Drug Costs for Beneficiaries
02/05/2025
Katie Hayes, MJ
On inauguration day, President Trump issued an executive order rescinding several Biden-era health care initiatives, including 3 experimental drug pricing models developed by the Center for Medicare and Medicaid Innovation (CMMI). Oh boy did...
On inauguration day, President Trump issued an executive order rescinding several Biden-era health care initiatives, including 3 experimental drug pricing models developed by the Center for Medicare and Medicaid Innovation (CMMI). Oh boy did...
On inauguration day, President...
02/05/2025
First Report Managed Care
Behind the Bill
Robert F. Kennedy Jr’s Confirmation and the Unexpected Turn in the Drug Pricing Debate
01/29/2025
Katie Hayes, MJ
The Plot Thickens in Drug Pricing Drama Just when you thought the drug pricing debate couldn't get more interesting, Robert F. Kennedy Jr adds an unexpected twist. During closed-door Senate meetings, President Trump’s US Department of...
The Plot Thickens in Drug Pricing Drama Just when you thought the drug pricing debate couldn't get more interesting, Robert F. Kennedy Jr adds an unexpected twist. During closed-door Senate meetings, President Trump’s US Department of...
The Plot Thickens in Drug...
01/29/2025
First Report Managed Care

Subscribe and Stay Ahead With Daily Industry Insights

First Report Managed Care Newsletter

Trending Articles

News
Improving Health Outcomes Through Early COPD and Asthma Intervention
10/04/2024
Hannah Musick
Research published in the New England Journal of Medicine shows that early diagnosis and treatment of undiagnosed COPD or asthma can reduce health care utilization for respiratory illness and improve overall health outcomes.
Research published in the New England Journal of Medicine shows that early diagnosis and treatment of undiagnosed COPD or asthma can reduce health care utilization for respiratory illness and improve overall health outcomes.
Research published in the New...
10/04/2024
First Report Managed Care
News
Advances in Factor IX Therapy Offer New Hope for Hemophilia B Treatment
10/23/2024
Lisa Kuhns, PhD, MD
New factor IX therapies promise improved treatment for hemophilia B.
New factor IX therapies promise improved treatment for hemophilia B.
New factor IX therapies promise...
10/23/2024
First Report Managed Care
News
JAK Inhibitor Improves Symptoms in Patients With Psoriatic Arthritis and Axial Involvement
04/21/2023
Jolynn Tumolo
In two phase 3 studies comparing upadacitinib to placebo and adalimumab, upadacitinib improved symptoms in patients with psoriatic arthritis and axial involvement.
In two phase 3 studies comparing upadacitinib to placebo and adalimumab, upadacitinib improved symptoms in patients with psoriatic arthritis and axial involvement.
In two phase 3 studies comparing...
04/21/2023
First Report Managed Care
News
Risk of Psychiatric Comorbidity Higher in Patients With Ankylosing Spondylitis
05/19/2023
Jolynn Tumolo
Findings from a population-based, cross-sectional study suggest that patients with ankylosing spondylitis are at a higher risk of developing psychiatric disorders.
Findings from a population-based, cross-sectional study suggest that patients with ankylosing spondylitis are at a higher risk of developing psychiatric disorders.
Findings from a...
05/19/2023
First Report Managed Care
Conference Coverage
Significant Number of Solid Tumor Drug Approvals Added Complexity to Existing Regimens
06/08/2023
Maria Asimopoulos
A significant portion of drug approvals for nonhematologic solid cancers in the last 12 years were for indications which added to existing regimens, which could increase costs and exposure to side effects, researchers said.
A significant portion of drug approvals for nonhematologic solid cancers in the last 12 years were for indications which added to existing regimens, which could increase costs and exposure to side effects, researchers said.
A significant portion of drug...
06/08/2023
First Report Managed Care

September 2011 Volume 8 Issue 9

View Issue Archive
Editorial Correspondence

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use